. 2019 Mar 27;155(6):700–707. doi: 10.1001/jamadermatol.2019.0001

Table 3. Adjusted Risk of Atrial Fibrillation and a Composite Cardiovascular Event in Patients With Psoriatic Disease Initiating Ustekinumab vs TNFi Therapy^a.

Outcome, Data Source	HR (95% CI)	Combined^b	Heterogeneity
Outcome, Data Source	HR (95% CI)	Combined^b	I², %	P Value^c
Atrial fibrillation
Optum	1.40 (0.81-2.41)	1.08 (0.76-1.54)	29.0	.24
MarketScan	0.95 (0.69-1.32)	1.08 (0.76-1.54)	29.0	.24
MACE^d
Optum	0.83 (0.46-1.50)	1.10 (0.80-1.52)	21.5	.26
MarketScan	1.21 (0.92-1.59)	1.10 (0.80-1.52)	21.5	.26

Abbreviations: HR, hazard rate; MACE, major adverse cardiovascular event; TNFi, tumor necrosis factor inhibitor.

^{^a}

Adjusted for the variables listed in eTable 1 in the Supplement using propensity-score stratification.

^{^b}

Combined using an inverse variance–weighted, random effects model.

^{^c}

P value of Q test for heterogeneity.

^{^d}

Composite cardiovascular event of myocardial infarction, stroke, and coronary revascularization.

Table 3. Adjusted Risk of Atrial Fibrillation and a Composite Cardiovascular Event in Patients With Psoriatic Disease Initiating Ustekinumab vs TNFi Therapya.